Ovid Therapeutics Inc. 8-K

What Happened

• Ovid Therapeutics (OVID) announced a private placement (PIPE) on March 17, 2026 under a Securities Purchase Agreement that is expected to raise approximately $60.0 million in gross proceeds (before placement agent fees and expenses). The financing includes the sale of 19,154,321 shares of common stock at $2.01 per share and issuance of pre-funded warrants to purchase up to 10,701,710 shares (purchased at $2.009 each). Each pre-funded warrant has a $0.001 exercise price and is immediately exercisable. The closing was expected on or about March 19, 2026.
• The company also filed a Registration Rights Agreement requiring it to file a registration statement for resale of the securities within 30 business days after closing and to use reasonable best efforts to have that registration declared effective within 60 days after filing (subject to exceptions and penalties). Ovid relied on the Section 4(a)(2) exemption for the unregistered sale.

Key Details

• Gross proceeds: ~$60.0 million (before fees and expenses).
• Securities offered: 19,154,321 common shares + pre-funded warrants for up to 10,701,710 shares (total potential shares = 29,856,031).
• Prices: $2.01 per common share; $2.009 per pre-funded warrant; warrant exercise price $0.001; warrants immediately exercisable.
• Placement agents: Leerink Partners (lead), Oppenheimer & Co. and LifeSci Capital (co-placement agents).
• Press release (filed March 18, 2026) announced new OV329 data, indication expansion, Phase 1 clearance for OV4071, and Q4/full-year 2025 financial results (Exhibit 99.1).

Why It Matters

• The financing provides Ovid with about $60M in additional capital to fund development of OV329 into additional indications (including tuberous sclerosis complex and infantile spasms) and for general R&D, which can extend the company’s development runway and advance its clinical programs.
• The use of pre-funded warrants (immediately exercisable at a nominal exercise price) and the potential issuance of nearly 30M shares could lead to dilution for existing shareholders once exercised/issued. The Registration Rights Agreement aims to make these securities freely tradable after the required SEC registration steps are completed.
• Investors should note this was a private, unregistered sale relying on SEC exemption (Section 4(a)(2)); the company must meet the registration timetable or face specified remedies under the agreement.